BRIEF published on 05/08/2024 at 12:35, 2 years 5 months ago Positive Results for the SOLARIS Phase 3 Trial of Olanzapine Schizophrenia Medincell SOLARIS Olanzapine TEV-'749
PRESS RELEASE published on 05/08/2024 at 12:30, 2 years 5 months ago Inside Information / Other news releases Teva and Medincell announce positive Phase 3 efficacy results from SOLARIS trial evaluating TEV-'749 (olanzapine) as a once-monthly subcutaneous long-acting injectable in adults with schizophrenia Schizophrenia Medincell Teva Phase 3 Efficacy Results SOLARIS Trial
BRIEF published on 05/08/2024 at 09:05, 2 years 5 months ago Medincell Temporarily Suspends its Euronext Paris Listing Euronext Paris Press Release Financial Markets Medincell Share Suspension
PRESS RELEASE published on 05/08/2024 at 09:00, 2 years 5 months ago Inside Information / Other news releases Medincell suspends listing of shares on Euronext Paris pending press release. Innovative biopharmaceutical company developing long-acting injectable drugs Euronext Paris Biopharmaceutical Suspension Medincell Long-acting Injectable Drugs
Published on 10/30/2026 at 23:35, 1 day 1 hour ago Prospect Ridge Announces Closing of Critical Metals Flow-through Unit Private Placement
Published on 10/30/2026 at 23:30, 1 day 1 hour ago Revolve Enters into Definitive Agreement to Acquire Three Project, 6 MW Battery Storage Portfolio in Ontario
Published on 10/30/2026 at 19:00, 1 day 6 hours ago Electric Royalties Ltd. Announces Application for Warrant Extension
Published on 10/30/2026 at 15:30, 1 day 9 hours ago Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split
Published on 10/31/2026 at 16:35, 8 hours 46 minutes ago SKYWORTH Solar Announces Global Launch of Solavita as a Smart Microgrid Brand
Published on 10/30/2026 at 22:49, 1 day 2 hours ago EQS-Adhoc: STRATEC SELLS LOSS-MAKING BUSINESS, RECOGNIZES IMPAIRMENTS, AND AMENDS GUIDANCE
Published on 10/30/2026 at 18:38, 1 day 6 hours ago EQS-Adhoc: Starcom Holding AD publishes Interim Q3 2026 Financial Report
Published on 10/30/2026 at 23:00, 1 day 2 hours ago BIOPHYTIS REPORTS FIRST- HALF 2026 RESULTS AND PROVIDES AN UPDATE ON ITS STRATEGY
Published on 10/30/2026 at 12:00, 1 day 13 hours ago Capital increase through exercise of subscription rights
